| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today announced that it has received formal confirmation from the Hearings Advisor (the "Hearings Advisor") of the Office of the General Counsel of the Nasdaq Hearings Panel (the "Nasdaq Hearings Panel") of The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with all applicable listing requirements.
In a letter dated August 13, 2025, the Hearings Advisor informed the Company that it has demonstrated compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2) and satisfied the conditions of the Nasdaq Hearings Panel's decision dated July 9, 2025.
This confirmation satisfies all conditions previously outlined by the Nasdaq Hearings Panel, and Polyrizon will continue to trade on the Nasdaq Capital Market under the ticker symbol "PLRZ."
Posted In: PLRZ
